A Phase I Trial of High-dose Continuous-infusion Hydroxyurea

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1993 Jan 1

PMID 8261572

Citations 1

Authors

D C Smith

W P Vaughan

P R Gwilt

D L Trump

Affiliations

Soon will be listed here.

Abstract

Hydroxyurea inhibits ribonucleotide reductase, resulting in depletion of intracellular deoxynucleotide pools and inhibition of DNA repair. It has been used in a variety of malignancies and is usually given orally. Deoxynucleotide depletion is directly related to the concentration of and duration of exposure to hydroxyurea; thus, prolonged continuous infusion may result in increased therapeutic efficacy. A total of 30 patients were treated on this trial, designed to determine the maximum tolerated doses (MTD) of intravenous hydroxyurea given as a 24- or 48-h continuous infusion. The MTD for the 24-h infusion was 13,520 mg/m2 following a bolus of 1,690 mg/m2, and the mean (+/- SD) plasma steady-state concentration was 1.93 +/- 0.52 mM. For the 48-h infusion, the MTD was 17,576 mg/m2 following a bolus of 2,197 mg/m2 and the mean steady-state level was 1.43 +/- 0.31 mM. The dose-limiting toxicity on both schedules was marrow suppression manifesting as neutropenia and thrombocytopenia. Pharmacokinetic analysis revealed decreasing clearance with increasing dose, implying that drug elimination is saturable. Pharmacodynamic analysis showed a slight correlation between steady-state plasma levels and the degree of marrow suppression.

Citing Articles

Cyanide, peroxide and nitric oxide formation in solutions of hydroxyurea causes cellular toxicity and may contribute to its therapeutic potency.

Kuong K, Kuzminov A J Mol Biol. 2009; 390(5):845-62.

PMID: 19467244 PMC: 2728359. DOI: 10.1016/j.jmb.2009.05.038.

References

Kennedy B . Hydroxyurea therapy in chronic myelogenous leukemia. Cancer. 1972; 29(4):1052-6. DOI: 10.1002/1097-0142(197204)29:4<1052::aid-cncr2820290454>3.0.co;2-7. View

Bianchi V, Pontis E, REICHARD P . Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem. 1986; 261(34):16037-42. View

ARIEL I . Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors. Cancer. 1970; 25(3):705-14. DOI: 10.1002/1097-0142(197003)25:3<705::aid-cncr2820250331>3.0.co;2-d. View

Belt R, Haas C, Kennedy J, Taylor S . Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer. 1980; 46(3):455-62. DOI: 10.1002/1097-0142(19800801)46:3<455::aid-cncr2820460306>3.0.co;2-n. View

Piver M, Vongtama V, Emrich L . Hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation in surgically staged stage IIIB cervical cancer. J Surg Oncol. 1987; 35(2):129-34. DOI: 10.1002/jso.2930350214. View

Akerblom L, Ehrenberg A, Graslund A, Lankinen H, REICHARD P, Thelander L . Overproduction of the free radical of ribonucleotide reductase in hydroxyurea-resistant mouse fibroblast 3T6 cells. Proc Natl Acad Sci U S A. 1981; 78(4):2159-63. PMC: 319303. DOI: 10.1073/pnas.78.4.2159. View

Matsumoto M, Rey D, CORY J . Effects of cytosine arabinoside and hydroxyurea on the synthesis of deoxyribonucleotides and DNA replication in L1210 cells. Adv Enzyme Regul. 1990; 30:47-59. DOI: 10.1016/0065-2571(90)90008-p. View

Pfeiffer S, Tolmach L . Inhibition of DNA synthesis in HeLa cells by hydroxyurea. Cancer Res. 1967; 27(1):124-9. View

Sharon R, Tatarsky I, Ben-Arieh Y . Treatment of polycythemia vera with hydroxyurea. Cancer. 1986; 57(4):718-20. DOI: 10.1002/1097-0142(19860215)57:4<718::aid-cncr2820570406>3.0.co;2-p. View

10.

Rosner F, Rubin H, Parise F . Studies on the absorption, distribution, and excretion of hydroxyurea (NSC-32065). Cancer Chemother Rep. 1971; 55(2):167-73. View

11.

Sinclair W . Hydroxyurea: effects on Chinese hamster cells grown in culture. Cancer Res. 1967; 27(2):297-308. View

12.

Veale D, Cantwell B, Kerr N, Upfold A, Harris A . Phase 1 study of high-dose hydroxyurea in lung cancer. Cancer Chemother Pharmacol. 1988; 21(1):53-6. DOI: 10.1007/BF00262739. View

13.

FABRICIUS E, Rajewsky F . Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin Biol. 1971; 16(7):679-83. View

14.

Ford S, Shackney S . Lethal and sublethal effects of hydroxyurea in relation to drug concentration and duration of drug exposure in sarcoma 180 in vitro. Cancer Res. 1977; 37(8 Pt 1):2628-37. View

15.

Carter S, Wasserman T . The chemotherapy of urologic cancer. Cancer. 1975; 36(2):729-47. DOI: 10.1002/1097-0142(197508)36:2+<729::aid-cncr2820360818>3.0.co;2-d. View

16.

Snyder R . Consequences of the depletion of cellular deoxynucleoside triphosphate pools on the excision-repair process in cultured human fibroblasts. Mutat Res. 1988; 200(1-2):193-9. DOI: 10.1016/0027-5107(88)90082-6. View

17.

Cantwell B, Veale D, Rivett C, Ghani S, Harris A . Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer. Cancer Chemother Pharmacol. 1989; 23(4):252-4. DOI: 10.1007/BF00451651. View

18.

Moran R, Straus M . Cytokinetic analysis of L1210 leukemia after continuous infusion of hydroxyurea in vivo. Cancer Res. 1979; 39(5):1616-22. View

19.

HRESHCHYSHYN M, ARON B, BORONOW R, Franklin 3rd E, SHINGLETON H, Blessing J . Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys. 1979; 5(3):317-22. DOI: 10.1016/0360-3016(79)91209-4. View